The global cardiac resynchronization therapy market size was valued at USD 5.09 billion in 2025 and is projected to grow from USD 5.31 billion in 2026 to USD 7.48 billion by 2034, registering a CAGR of 4.37% during the forecast period from 2026 to 2034. North America dominated the cardiac resynchronization therapy market with a market share of 41.5% in 2025.
The cardiac resynchronization therapy market is growing steadily as cardiovascular diseases, particularly heart failure, continue to rise globally, with over 64 million people affected worldwide. Aging populations and lifestyle risks are key contributors. Increasing awareness of early diagnosis is improving adoption of advanced CRT devices. Leading companies such as Medtronic, Abbott Laboratories, and Boston Scientific are driving innovation with MRI-compatible devices and remote monitoring systems, enhancing treatment outcomes.
For instance, Medtronic’s CRT-D systems integrate wireless patient monitoring for better disease management. Favorable reimbursement policies in developed regions support accessibility, while emerging markets grow due to improving cardiac care infrastructure. Additionally, clinical studies show CRT reduces hospitalization risk by nearly 30% in heart failure patients. However, high device costs and limited access in low-income regions continue to restrain market expansion despite strong demand.
Download a Free Sample To learn more about this report,
Increasing Adoption of Advanced Pacing Technologies for Cardiac Resynchronization
Cardiac resynchronization therapy is increasingly incorporating advanced pacing approaches designed to improve ventricular synchronization and procedural precision. Conduction system pacing, including His-bundle and left bundle branch area pacing, is gaining attention as clinicians seek alternatives that can provide more physiological electrical activation and address limitations associated with conventional biventricular pacing.
Growing Adoption of CRT-Defibrillator Systems for Combined Heart Failure and Arrhythmia Management
CRT-defibrillator systems are increasingly used when patients require both ventricular resynchronization and protection from life-threatening ventricular arrhythmias. The combination of pacing and defibrillation capabilities can provide broader cardiac management within a single implanted system, supporting continued demand for advanced CRT devices among appropriately selected heart failure patients.
Rising Prevalence of Heart Failure and Cardiac Conduction Disorders Supports Cardiac Resynchronization Therapy Market Growth
The growing burden of heart failure and associated electrical conduction abnormalities is increasing the population eligible for advanced cardiac device therapy. Patients with reduced left ventricular function, prolonged QRS duration, and appropriate conduction abnormalities can benefit from CRT to improve ventricular coordination, symptoms, and clinical outcomes, supporting continued demand for implantation procedures.
High Device and Implantation Costs Can Limit Cardiac Resynchronization Therapy Adoption
CRT systems require specialized implantable devices, leads, imaging equipment, electrophysiology expertise, and post-implant programming and monitoring. The combined cost of the device and procedure can limit access in healthcare systems with constrained budgets or inadequate reimbursement, particularly where advanced cardiac device infrastructure is concentrated in major medical centers.
Expansion of CRT Across Emerging Cardiac Care Infrastructure Creates New Growth Opportunities
Expansion of specialized cardiac centers, improving access to electrophysiology services, and development of cardiovascular infrastructure in emerging markets are creating opportunities for broader CRT adoption. Greater availability of advanced imaging, cardiac device implantation capabilities, reimbursement coverage, and specialist expertise can increase access to resynchronization therapy among eligible heart failure patients.
Patient Selection, Procedural Complexity, and Variable Treatment Response Create Challenges
CRT effectiveness depends on appropriate patient selection, lead positioning, electrical conduction characteristics, and successful device programming. Not all heart failure patients respond equally to resynchronization, while implantation can be technically demanding in patients with challenging venous anatomy or complex conduction patterns, creating ongoing clinical and procedural challenges.
Sub-cutaneous CRT-D Segment is Projected to Register the Fastest Growth at a CAGR of 6.08%
The sub-cutaneous CRT-D segment is projected to register the fastest growth at a CAGR of 6.08% during 2026–2034. In 2025, the segment accounted for 14.7% of the global cardiac resynchronization therapy market, with a value of USD 0.75 billion. Growth is driven by increasing demand for advanced cardiac rhythm management devices, rising prevalence of heart failure, and continued improvements in implantable cardiac technologies. Growing adoption of less invasive approaches and technological advancements in device design continue to support the segment's growth.
The transvenous CRT-D segment dominated the market with a 52.8% share and a value of USD 2.69 billion, owing to its established clinical use and widespread adoption for patients requiring cardiac resynchronization and defibrillation. Dual/biventricular CRT-P accounted for 21.6% of the market, while single-chamber CRT-P represented 10.9%. These devices continue to support market growth through increasing demand for cardiac rhythm management and heart failure treatment.
Request Customizationto receive a tailored report.
Ambulatory Surgical Centers Segment is Projected to Register the Fastest Growth at a CAGR of 6.12%
The ambulatory surgical centers segment is projected to register the fastest growth at a CAGR of 6.12% during 2026–2034. In 2025, the segment accounted for 11.8% of the global cardiac resynchronization therapy market, with a value of USD 0.60 billion. Growth is driven by the increasing shift toward minimally invasive cardiac procedures, shorter hospital stays, lower healthcare costs, and the expanding availability of specialized cardiac procedures in outpatient settings.
The hospitals segment dominated the market with a 55.7% share and a value of USD 2.84 billion, owing to the availability of advanced cardiac care infrastructure, specialized cardiology professionals, and high volumes of cardiac procedures. Cardiac centers accounted for 27.3% of the market and continue to witness demand due to their specialized capabilities in heart failure management and cardiac device implantation. Other end users represented 5.2% of the market.
Speak to an Analystto discuss market opportunities.
North America cardiac resynchronization therapy market accounted for 41.5% of the global market, reaching USD 2.11 billion in 2025, and is projected to grow at a CAGR of 5.12% during the forecast period. The market is driven by the increasing prevalence of heart failure, growing adoption of advanced cardiac devices, rising healthcare expenditure, and increasing demand for minimally invasive cardiac procedures. Technological advancements in CRT devices and expanding access to specialized cardiac care continue to support regional market growth.
The US market was valued at USD 1.79 billion in 2025, making it the largest contributor in North America. Increasing prevalence of heart failure, growing adoption of cardiac implantable devices, rising healthcare expenditure, and advancements in cardiac resynchronization technologies continue to drive market growth.
Canada's market reached USD 0.32 billion in 2025. Growing cardiovascular disease burden, increasing demand for advanced cardiac care, expanding healthcare infrastructure, and rising adoption of implantable cardiac devices continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe cardiac resynchronization therapy market accounted for 28.4% of the global market, reaching USD 1.45 billion in 2025, and is projected to grow at a CAGR of 4.86% during the forecast period. Increasing prevalence of cardiovascular diseases, growing demand for heart failure management, expanding access to advanced cardiac technologies, and rising healthcare investments continue to strengthen regional market growth. Improvements in cardiac care infrastructure and increasing adoption of implantable devices further support market expansion.
The UK market was valued at USD 0.29 billion in 2025. Increasing prevalence of heart failure, growing demand for advanced cardiac treatment, expanding access to implantable devices, and rising investments in cardiovascular healthcare continue to support market growth.
Germany market accounted for USD 0.41 billion in 2025. Strong cardiac care infrastructure, increasing cardiovascular disease burden, growing adoption of advanced cardiac devices, and rising healthcare expenditure continue to drive market expansion.
Asia Pacific cardiac resynchronization therapy market accounted for 20.6% of the global market, reaching USD 1.05 billion in 2025, and is projected to grow at a CAGR of 6.71% during the forecast period. Rising prevalence of cardiovascular diseases, expanding healthcare infrastructure, increasing healthcare expenditure, and growing awareness of advanced heart failure treatments continue to accelerate regional market growth. Increasing availability of specialized cardiac care and adoption of innovative implantable devices further strengthen market expansion.
China's market accounted for USD 0.44 billion in 2025, representing the largest share within Asia Pacific. Increasing cardiovascular disease burden, expanding healthcare infrastructure, growing access to advanced cardiac procedures, and rising adoption of implantable cardiac devices continue to drive market expansion.
Japan's market generated USD 0.19 billion in 2025. Increasing aging population, growing prevalence of heart failure, expanding adoption of advanced cardiac technologies, and rising investments in cardiovascular care continue to support market growth.
Middle East and Africa cardiac resynchronization therapy market accounted for 4.1% of the global market, totaling USD 0.21 billion in 2025, and is projected to grow at a CAGR of 5.09% during the forecast period. Increasing investments in healthcare infrastructure, growing prevalence of cardiovascular diseases, expanding access to specialized cardiac care, and rising adoption of advanced cardiac devices continue to support regional market growth.
The UAE market was valued at USD 0.05 billion in 2025. Increasing investments in advanced cardiac care facilities, growing medical tourism, rising prevalence of cardiovascular diseases, and expanding adoption of implantable cardiac devices continue to drive market growth.
Africa's market reached USD 0.16 billion in 2025. Expanding healthcare access, increasing investments in cardiovascular infrastructure, growing awareness of advanced heart failure treatments, and rising demand for specialized cardiac devices continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Aerosol Delivery Devices Market Size, Share, Growth, 2034
Artificial Cornea and Corneal Implant Market Size, Share, 2034
Active Wheelchair Market Size, Share, Growth, Forecast, 2034
Alpha Emitter Market Size, Share, Growth, Analysis, Report, 2034
Advanced Wound Care Market Size, Share, Growth, Analysis, 2034
Acute Wound Care Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com